Last updated on November 2017

THE SHP-GCB-402 STUDY FOR GAUCHER DISEASE


Brief description of study

THE SHP-GCB-402 STUDY FOR GAUCHER DISEASE

Detailed Study Description

The SHP-GCB-402 study for Gaucher disease is evaluating the effect velaglucerase alfa (VPRIV®) has on bone pain and bone density in people with type I Gaucher disease.

Clinical Study Identifier: TX14855

Contact Investigators or Research Sites near you

Start Over
Sorry. There are no research Sites conducting this study in the radius provided. ( View all Sites )